Overview
- Product nameAnti-Apolipoprotein E antibodySee all Apolipoprotein E primary antibodies ...
- DescriptionRabbit polyclonal to Apolipoprotein E
- SpecificityAb20874 is extremely low recognition of human Apo E. No data available regarding rat activity. We have data to indicate that this antibody may not cross react with Human. However, this has not been conclusively tested and expression levels may vary in certain cell lines/tissues.
- Tested applicationsRID, Immunodiffusion, Immunoelectrophoresis, WB, IHC-Fr more details
- Species reactivityReacts with: Mouse, Rat
- Immunogen
Full length purified Mouse Apolipoprotein E from pooled mouse plasma high and very low density lipoproteins.
Properties
- FormLiquid
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPreservative: 0.05% Sodium Azide
- PurityWhole antiserum
- Purification notesThe product is heat inactivated and 0.22um filtered.
- Clonality Polyclonal
- IsotypeIgG
- Research Areas
Applications
Our Abpromise guarantee covers the use of ab20874 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Notes |
|---|---|
| RID | RID: Use at an assay dependent dilution. |
| Immunodiffusion | ID: Use at an assay dependent dilution. |
| Immunoelectrophoresis | Ie: Use at an assay dependent dilution. |
| WB | WB: 1/500 - 1/1000. Predicted molecular weight: 36 kDa. Dilution optimised using Chromogenic detection. |
| IHC-Fr | IHC-Fr: Use at an assay dependent dilution. PubMed: 20505763 |
Target
- FunctionMediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.
- Tissue specificityOccurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
- Involvement in diseaseDefects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3) [MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD.
Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2) [MIM:104310]. It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Note=The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.
Defects in APOE are a cause of sea-blue histiocyte disease (SBHD) [MIM:269600]; also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.
Defects in APOE are a cause of lipoprotein glomerulopathy (LPG) [MIM:611771]. LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians. - Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
- Post-translational
modificationsSynthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 is a minor glycosylation site compared to Ser-308.
Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).
Phosphorylation sites are present in the extracelllular medium. - Cellular localizationSecreted.
-
Database links
- Entrez Gene: 11816 Mouse
- Entrez Gene: 25728 Rat
- SwissProt: P08226 Mouse
- SwissProt: P02650 Rat
- Unigene: 305152 Mouse
- Unigene: 32351 Rat
Target information above from: UniProt accession
P02649
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010)
.
-
Alternative names
- AD2 antibodyAlzheimer disease 2 antibodyApo E antibody
- Apo-E antibodyApoE antibodyAPOE_HUMAN antibodyAPOEA antibodyApolipoprotein E antibodyApolipoprotein E3 antibodyApolipoproteinE antibodyApoprotein antibodyLDLCQ5 antibodyLPG antibodyMGC1571 antibody
see all
Anti-Apolipoprotein E antibody images
-
Western blot - Apolipoprotein E antibody (ab20874)Anti-Apolipoprotein E antibody (ab20874) + 20ug rat hippocampal lysate
Secondary
anti-rabit HRP-labeled secondary antibody
Predicted band size : 36 kDaS Kanazir, Inst Biol Res, Yugoslavia
-
Immunohistochemistry (Frozen sections) - Apolipoprotein E antibody (ab20874)Image from Laurén HB et al, PLoS One. 2010 May 20;5(5):e10733, Fig 5.ab20874 staining Apolipoprotein E in rat brain tissue by Immunohistochemistry (Frozen sections). After fixation in 4% PFA in PBS (pH 7.4), brains were cryoprotected in 30% sucrose in PBS at +4°C, frozen, and thereafter kept at -80°C until used. For the immunostaining, brains were cryosectioned in 30 µm slices, collected in PBS (pH 7.4), and processed in a free-floating system. Slices were first incubated in the blocking solution (BS) containing 2% bovine serum albumin, 2% goat serum, and 0.1% Triton X-100 in PBS (pH 7.4) for 1 hour at room temperature, and thereafter with the primary antibody for 24–48 hours at +4°C in BS at a 1/1000 dilution. After washing in PBS, slices were incubated with the biotin-conjugated secondary antibody (1/4000) in BS, rinsed with PBS, and incubated with the avidin-peroxidase conjugate in BS for 1 hour at room temperature. The staining was detected using 3,3-diaminobenzidinetetrahydrochloride as a chromogen.
References for Anti-Apolipoprotein E antibody (ab20874)
This product has been referenced in:
- Da Costa D et al. Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J Virol 86:11919-25 (2012). WB ; Mouse . Read more (PubMed: 22896615) »
- Terwel D et al. Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-{alpha} Expression for Microglial A{beta} Phagocytosis. J Neurosci 31:7049-59 (2011). Read more (PubMed: 21562267) »
